mesothelioma / Posted 1 year ago
ORPHA:168811 Malignant peritoneal mesothelioma ORPHA:168816 Peritoneal cystic mesothelioma ORPHA:50251 Pleural mesothelioma
CheckpOiNt blockade For Inhibition of Relapsed Mesothelioma (CONFIRM): A Phase III Trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma
Researchers want to find out if nivolumab can help these people.
Nivolumab is a type of immunotherapy drug called a monoclonal antibody. It works by stimulating the body’s immune system to recognise and kill cancer cells.
We know from research that nivolumab could help people whose mesothelioma has come back after chemotherapy. But it isn’t known if it as good as active symptom control.
In this trial most people will have nivolumab and some will have a dummy drug (placebo).
The main aims of the trial are to find:
- how well nivolumab works for people whose mesothelioma has come back after chemotherapy
- how safe it is
- how it affects quality of life